{
    "xml": "<topic id=\"PHP18937\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/dapagliflozin\" basename=\"dapagliflozin\" title=\"DAPAGLIFLOZIN\">\n<title>DAPAGLIFLOZIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1239\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/dapagliflozin\">Dapagliflozin</xref>\n</p>\n<data name=\"vtmid\">703678003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_387708906\" title=\"Sodium glucose co-transporter 2 inhibitors\">Sodium glucose co-transporter 2 inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP41073\" outputclass=\"drugAction\" rev=\"1.9\" parent=\"/drugs/dapagliflozin\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41059\" outputclass=\"indicationsAndDose\" rev=\"1.27\" parent=\"/drugs/dapagliflozin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus as monotherapy if metformin inappropriate</p>\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years</p>\n<p>10&#8239;mg once daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 75 years and over</p>\n<p>Initiation not recommended.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41074\" outputclass=\"importantSafetyInformation\" rev=\"1.19\" parent=\"/drugs/dapagliflozin\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice (June 2015): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin or empagliflozin)</p>\n<p>Serious and potentially life-threatening cases of diabetic ketoacidosis (DKA) have been reported in patients taking the SGLT2 inhibitor dapagliflozin for type 2 diabetes. To minimise the risk of such effects when treating patients with a SGLT2 inhibitor, the European Medicines Agency has issued the following advice:</p>\n<ul>\n<li>Test for raised ketones in patients presenting with symptoms of DKA, even if plasma glucose levels are near-normal; omitting this test could delay diagnosis of DKA.</li>\n<li>Discontinue treatment if DKA is suspected.</li>\n<li>If DKA is confirmed, take appropriate measures to correct the DKA and monitor glucose levels.</li>\n<li>Patients should be advised on how to recognise the signs and symptoms of DKA such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, or sleepiness, and to seek prompt medical attention if symptoms of DKA develop.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41077\" outputclass=\"contraindications\" rev=\"1.5\" parent=\"/drugs/dapagliflozin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Ketoacidosis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41083\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/dapagliflozin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cardiovascular disease (risk of hypotension)</ph>; <ph outputclass=\"caution\">elderly (risk of hypotension)</ph>; <ph outputclass=\"caution\">electrolyte disturbances</ph>; <ph outputclass=\"caution\">hypotension</ph>; <ph outputclass=\"caution\">raised haematocrit</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Volume depletion</p>\n<p>Correct hypovolaemia before starting treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41055\" outputclass=\"interactions\" rev=\"1.5\" parent=\"/drugs/dapagliflozin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41025\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/dapagliflozin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Back pain</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">dyslipidaemia</ph>; <ph outputclass=\"sideEffect\">dysuria</ph>; <ph outputclass=\"sideEffect\">genital infection</ph>; <ph outputclass=\"sideEffect\">hypoglycaemia (in combination with insulin or sulphonylurea)</ph>; <ph outputclass=\"sideEffect\">polyuria</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">thirst</ph>; <ph outputclass=\"sideEffect\">urinary-tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dehydration</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">hypovolaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">nocturia</ph>; <ph outputclass=\"sideEffect\">raised serum creatinine</ph>; <ph outputclass=\"sideEffect\">raised serum urea</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Volume depletion</p>\n<p>Consider interrupting treatment if volume depletion occurs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41045\" outputclass=\"pregnancy\" parent=\"/drugs/dapagliflozin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41084\" outputclass=\"breastFeeding\" parent=\"/drugs/dapagliflozin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41065\" outputclass=\"hepaticImpairment\" parent=\"/drugs/dapagliflozin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Initial dose 5&#8239;mg daily in severe impairment, increased according to response.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41034\" outputclass=\"renalImpairment\" parent=\"/drugs/dapagliflozin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (ineffective).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41005\" outputclass=\"monitoringRequirements\" parent=\"/drugs/dapagliflozin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Determine renal function before treatment and at least annually thereafter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41042\" outputclass=\"patientAndCarerAdvice\" rev=\"1.23\" parent=\"/drugs/dapagliflozin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients should be informed of the signs and symptoms of diabetic ketoacidosis, see MHRA advice.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40987\" outputclass=\"nationalFunding\" rev=\"1.19\" parent=\"/drugs/dapagliflozin\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA288</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dapagliflozin in combination therapy for treating type 2 diabetes (June 2013)</p>\r\n<p>Dapagliflozin in a dual therapy regimen in combination with metformin is recommended for the treatment of type 2 diabetes, only if glycaemic control is inadequate, and the patient has a significant risk of hypoglycaemia <i>or</i> if a sulfonylurea is contra-indicated or not tolerated.</p>\r\n<p>Dapagliflozin in combination with insulin (alone or with other antidiabetic drugs) is an option for the treatment of type 2 diabetes.</p>\r\n<p>Dapagliflozin in combination with metformin and a sulfonylurea as triple therapy is not recommended for the treatment of type 2 diabetes except as part of a clinical trial.</p>\r\n<p>Patients currently receiving dapagliflozin in a dual or triple therapy regimen that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA288\">www.nice.org.uk/TA288</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised that dapagliflozin (<i>Forxiga</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin, when treatment with metformin alone is inadequate and a sulfonylurea is inappropriate (December 2012), or in combination with insulin when treatment with insulin alone is inadequate (February 2014).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP18937-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/dapagliflozin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101291\" title=\"Tablet\" namespace=\"/drugs/dapagliflozin/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85589\" namespace=\"/drugs/dapagliflozin-with-metformin\" title=\"DAPAGLIFLOZIN WITH METFORMIN\" count=\"1\" rel=\"backlink\">DAPAGLIFLOZIN WITH METFORMIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"3\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1239\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/dapagliflozin\" title=\"Dapagliflozin\" count=\"1\" rel=\"link\">Dapagliflozin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101291\" namespace=\"/drugs/dapagliflozin/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP18937",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/dapagliflozin",
    "basename": "dapagliflozin",
    "title": "DAPAGLIFLOZIN",
    "interactants": [
        {
            "id": "bnf_int_1239",
            "label": "Dapagliflozin"
        }
    ],
    "vtmid": "703678003",
    "drugClassification": [
        "Sodium glucose co-transporter 2 inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.",
                "html": "<p>Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus as monotherapy if metformin inappropriate",
                        "html": "Type 2 diabetes mellitus as monotherapy if metformin inappropriate"
                    },
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)",
                        "html": "Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "10 mg once daily.",
                        "html": "<p>10&#8239;mg once daily.</p>",
                        "ageGroup": "18&#8211;74 years"
                    },
                    {
                        "textContent": "Initiation not recommended.",
                        "html": "<p>Initiation not recommended.</p>",
                        "ageGroup": "75 years and over"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.",
                "html": "<p>Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice (June 2015): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin or empagliflozin)",
                "textContent": "Serious and potentially life-threatening cases of diabetic ketoacidosis (DKA) have been reported in patients taking the SGLT2 inhibitor dapagliflozin for type 2 diabetes. To minimise the risk of such effects when treating patients with a SGLT2 inhibitor, the European Medicines Agency has issued the following advice:\n\nTest for raised ketones in patients presenting with symptoms of DKA, even if plasma glucose levels are near-normal; omitting this test could delay diagnosis of DKA. Discontinue treatment if DKA is suspected. If DKA is confirmed, take appropriate measures to correct the DKA and monitor glucose levels. Patients should be advised on how to recognise the signs and symptoms of DKA such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, or sleepiness, and to seek prompt medical attention if symptoms of DKA develop.",
                "html": "<p>Serious and potentially life-threatening cases of diabetic ketoacidosis (DKA) have been reported in patients taking the SGLT2 inhibitor dapagliflozin for type 2 diabetes. To minimise the risk of such effects when treating patients with a SGLT2 inhibitor, the European Medicines Agency has issued the following advice:</p><ul>\n<li>Test for raised ketones in patients presenting with symptoms of DKA, even if plasma glucose levels are near-normal; omitting this test could delay diagnosis of DKA.</li>\n<li>Discontinue treatment if DKA is suspected.</li>\n<li>If DKA is confirmed, take appropriate measures to correct the DKA and monitor glucose levels.</li>\n<li>Patients should be advised on how to recognise the signs and symptoms of DKA such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, or sleepiness, and to seek prompt medical attention if symptoms of DKA develop.</li>\n</ul>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Ketoacidosis",
                "html": "Ketoacidosis"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cardiovascular disease (risk of hypotension)",
                "html": "Cardiovascular disease (risk of hypotension)"
            },
            {
                "type": "cautions",
                "textContent": "elderly (risk of hypotension)",
                "html": "elderly (risk of hypotension)"
            },
            {
                "type": "cautions",
                "textContent": "electrolyte disturbances",
                "html": "electrolyte disturbances"
            },
            {
                "type": "cautions",
                "textContent": "hypotension",
                "html": "hypotension"
            },
            {
                "type": "cautions",
                "textContent": "raised haematocrit",
                "html": "raised haematocrit"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Volume depletion",
                "textContent": "Correct hypovolaemia before starting treatment.",
                "html": "<p>Correct hypovolaemia before starting treatment.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Back pain",
                        "html": "Back pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyslipidaemia",
                        "html": "dyslipidaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dysuria",
                        "html": "dysuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "genital infection",
                        "html": "genital infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypoglycaemia (in combination with insulin or sulphonylurea)",
                        "html": "hypoglycaemia (in combination with insulin or sulphonylurea)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "polyuria",
                        "html": "polyuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "thirst",
                        "html": "thirst",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary-tract infection",
                        "html": "urinary-tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dehydration",
                        "html": "Dehydration",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypovolaemia",
                        "html": "hypovolaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nocturia",
                        "html": "nocturia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "raised serum creatinine",
                        "html": "raised serum creatinine",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "raised serum urea",
                        "html": "raised serum urea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Volume depletion",
                "textContent": "Consider interrupting treatment if volume depletion occurs.",
                "html": "<p>Consider interrupting treatment if volume depletion occurs.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal </i>studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Initial dose 5 mg daily in severe impairment, increased according to response.",
                "html": "<p>Initial dose 5&#8239;mg daily in severe impairment, increased according to response.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if eGFR less than 60 mL/minute/1.73 m2 (ineffective).",
                "html": "<p>Avoid if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (ineffective).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Determine renal function before treatment and at least annually thereafter.",
                "html": "<p>Determine renal function before treatment and at least annually thereafter.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients should be informed of the signs and symptoms of diabetic ketoacidosis, see MHRA advice.",
                "html": "<p>Patients should be informed of the signs and symptoms of diabetic ketoacidosis, see MHRA advice.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA288",
                        "label": "www.nice.org.uk/TA288"
                    }
                ],
                "fundingIdentifier": "NICE TA288",
                "textContent": "Dapagliflozin in combination therapy for treating type 2 diabetes (June 2013) Dapagliflozin in a dual therapy regimen in combination with metformin is recommended for the treatment of type 2 diabetes, only if glycaemic control is inadequate, and the patient has a significant risk of hypoglycaemia or if a sulfonylurea is contra-indicated or not tolerated. Dapagliflozin in combination with insulin (alone or with other antidiabetic drugs) is an option for the treatment of type 2 diabetes. Dapagliflozin in combination with metformin and a sulfonylurea as triple therapy is not recommended for the treatment of type 2 diabetes except as part of a clinical trial. Patients currently receiving dapagliflozin in a dual or triple therapy regimen that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA288",
                "html": "<p outputclass=\"title\">Dapagliflozin in combination therapy for treating type 2 diabetes (June 2013)</p> <p>Dapagliflozin in a dual therapy regimen in combination with metformin is recommended for the treatment of type 2 diabetes, only if glycaemic control is inadequate, and the patient has a significant risk of hypoglycaemia <i>or</i> if a sulfonylurea is contra-indicated or not tolerated.</p> <p>Dapagliflozin in combination with insulin (alone or with other antidiabetic drugs) is an option for the treatment of type 2 diabetes.</p> <p>Dapagliflozin in combination with metformin and a sulfonylurea as triple therapy is not recommended for the treatment of type 2 diabetes except as part of a clinical trial.</p> <p>Patients currently receiving dapagliflozin in a dual or triple therapy regimen that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA288\">www.nice.org.uk/TA288</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP101291",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85589",
                "label": "DAPAGLIFLOZIN WITH METFORMIN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1239",
                "label": "Dapagliflozin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP101291",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}